Eledon Pharmaceuticals, Inc. Additional Paid in Capital, Common Stock
Eledon Pharmaceuticals, Inc. (ELDN) had Additional Paid in Capital, Common Stock of $504.90 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent › Additional Paid in Capital
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-13
- 2026-06-30: Additional Paid in Capital, Common Stock $504.90M.
- 2026-03-31: Additional Paid in Capital, Common Stock $484.99M.
- 2025-12-31: Additional Paid in Capital, Common Stock $482.19M.
- 2025-09-30: Additional Paid in Capital, Common Stock $426.05M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $504.90M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $484.99M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $482.19M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $426.05M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $423.62M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $420.93M 10-Q/A · filed 2025-08-14 | $476.62M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $417.95M 10-K · filed 2026-03-19 | $473.64M 10-K · filed 2025-03-20 |
| 2024-09-30 | $331.19M 10-Q · filed 2025-11-14 | $386.88M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $323.71M 10-Q · filed 2025-08-14 | $379.40M 10-Q · filed 2024-08-19 |
| 2024-03-31 | $328.28M 10-Q/A · filed 2024-08-19 | |
| 2023-12-31 | $270.89M 10-K/A · filed 2025-08-14 | $326.59M 10-K · filed 2024-03-28 |
| 2023-09-30 | $324.88M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $323.14M 10-K/A · filed 2024-08-19 | |
| 2023-03-31 | $288.42M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $287.03M 10-K/A · filed 2024-08-19 | |
| 2022-09-30 | $285.56M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $283.38M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $281.07M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $278.88M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $276.83M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $274.78M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $272.75M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $270.97M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $95.99M 10-Q · filed 2020-11-16 | |
| 2020-06-30 | $77.68M 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $77.49M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $67.05M 10-K · filed 2021-03-31 | $67.03M 10-K · filed 2020-03-17 |
| 2019-09-30 | $66.79M 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $66.56M 10-Q · filed 2019-08-13 | |
| 2019-03-31 | $56.37M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $56.05M 10-K · filed 2020-03-17 | |
| 2018-09-30 | $55.31M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $55.01M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $54.60M 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $46.95M 10-K · filed 2019-03-28 | |
| 2017-09-30 | $46.01M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $45.86M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $196.60M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $11.38M 10-K · filed 2018-04-02 | $196.23M 10-K · filed 2017-03-03 |
| 2016-09-30 | $195.89M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $195.25M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $194.25M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $193.19M 10-K · filed 2017-03-03 | |
| 2015-09-30 | $192.29M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $191.30M 10-Q · filed 2015-08-12 | |
| 2014-12-31 | $189.83M 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |